Fedratinib – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 54 min read

Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

On this page12 sections

Article Summary

Fedratinib is an orally bioavailable, small-molecule, ATP-competitive inhibitor of Janus-associated kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, fedratinib competes with wild-type JAK2 as well as mutated forms for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, inhibition of tumor cell proliferation and induction of tumor cell apoptosis. JAK2 is the...

Key Takeaways

This article explains Mechanism of Action in simple medical language.
This article explains Indications in simple medical language.
This article explains Contraindications in simple medical language.
This article explains Dosage in simple medical language.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.

Educational health guideWritten for patient understanding and clinical awareness.

Reviewed content workflowUse writer and reviewer profiles for stronger trust.

Emergency safety firstUrgent warning signs are highlighted below.

Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Evidence Trust Passport

How this article is supported

79/100

Written byDr. Harun Ar Rashid, MD - Arthritis, Bones, Joints Pain, Trauma, and Internal Medicine Specialist

Medical review1 reviewer

Last reviewedNot scheduled

Next reviewNot scheduled

References1 source entry

Review statusReview schedule needed

Medical library classification Drug monograph Diseases A–Z

This passport makes the article’s review, evidence, and update signals visible. It does not guarantee that every section is complete or replace personal medical advice.

Definition

Fedratinib is an orally bioavailable, small-molecule, ATP-competitive inhibitor of Janus-associated kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, fedratinib competes with wild-type JAK2 as well as mutated forms for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, inhibition of tumor cell proliferation and induction of tumor cell apoptosis. JAK2 is the most commonly mutated gene in bcr-abl-negative myeloproliferative disorders (MPDs). In addition, fedratinib targets bind to and inhibit the activity of FLT3. This inhibits uncontrolled FLT3 signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias and plays a key role in tumor cell proliferation.

Fedratinib is an oral selective inhibitor of Janus-associated kinase 2 (JAK-2) and FMS-like tyrosine kinase 3 (FLT3) that is used in the therapy of intermediate or high-risk, primary or secondary myelofibrosis. Fedratinib has been associated with a high rate of serum enzyme elevations during therapy but has been associated with only rare instances of clinically apparent acute liver injury.

Fedratinib Hydrochloride is the monohydrate dihydrochloride salt form of fedratinib, an orally bioavailable, small-molecule, ATP-competitive inhibitor of Janus-associated kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, fedratinib competes with wild-type JAK2 as well as mutated forms for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, inhibition of tumor cell proliferation and induction of tumor cell apoptosis. JAK2 is the most commonly mutated gene in bcr-abl-negative myeloproliferative disorders (MPDs). In addition, fedratinib targets bind to, and inhibit the activity of FLT3. This inhibits uncontrolled FLT3 signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias and plays a key role in tumor cell proliferation.

Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high-risk primary and secondary myelofibrosis. It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019.

Mechanism of Action

Fedratinib is an inhibitor of Janus Activated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3. JAK2 is highly active in myeloproliferative neoplasms like myelofibrosis. Fedratinib’s inhibition of JAK2 inhibits phosphorylation of signal transducer and activator of transcription (STAT) 3 and 5, which prevents cell division and induces apoptosis.

Fedratinib is a kinase inhibitor that inhibits cell division and induces apoptosis. Patients taking fedratinib may experience anemia, thrombocytopenia, gastrointestinal toxicity, hepatic toxicity, or elevated amylase and lipase. These effects should be managed by reducing the dose, temporarily stopping the medication, or providing transfusions on a case-by-case basis.

Fedratinib acts as a competitive inhibitor of protein kinase JAK-2 with IC₅₀=6 nM; related kinases FLT3 and RET are also sensitive, with IC₅₀=25 nM and IC₅₀=17 nM, respectively. Significantly less activity was observed against other tyrosine kinases including JAK3 (IC₅₀=169 nM). In treated cells, the inhibitor blocks downstream cellular signaling (JAK-STAT) leading to the suppression of proliferation and induction of apoptosis.

Indications

Fedratinib is indicated to treat adults with primary or secondary myelofibrosis that is either intermediate-2 or high-risk.
Arabic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythemia vera myelofibrosis, or post essential thrombocythaemia myelofibrosis who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.
Fedratinib is an oral selective inhibitor of Janus-associated kinase 2 (JAK-2) and FMS-like tyrosine kinase 3 (FLT3) that is used in the therapy of intermediate or high-risk, primary or secondary myelofibrosis
Fedratinib hydrochloride is approved for use in adults to treat: Myelofibrosis (a bone marrow disease) that is an intermediate-2 risk or high risk, including the following types: Primary myelofibrosis. Post-polycythemia vera myelofibrosis. Post-essential thrombocythemia myelofibrosis.
Fedratinib hydrochloride is also being studied in the treatment of other conditions.
For the treatment of intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF)
In the United States, fedratinib is indicated for the treatment of adults with intermediate-2 or high-risk primary or secondary (following polycythemia vera or essential thrombocythemia) myelofibrosis.
Primary Myelofibrosis (PMF)
Secondary Myelofibrosis

Use in Cancer

Toremifene is approved to treat:

Breast cancer that has metastasized (spread to other parts of the body). It is used in postmenopausal women whose cancer is estrogen receptor-positive (ER+) or when it is not known if the cancer is ER+ or estrogen receptor-negative (ER-).

Contraindications

A High Alanine Transaminase Level
A High Aspartate Transaminase Level
Low Amount Of Sodium In The Blood
Decreased Blood Platelets
A Type Of Brain Function Problem Called Encephalopathy
High Blood Pressure
A Low Supply Of Oxygen Rich Blood To The Heart
Heart Failure
High Blood Levels Of The Lipase Enzyme
High Blood Levels Of The Amylase Enzyme
Difficult Or Painful Urination
Wernicke’s Encephalopathy

Dosage

Strengths: 100 mg

Myelofibrosis

For patients with a baseline platelet count of 50 x 109/L or greater:

400 mg orally once a day

Management of thiamine levels and Wernicke’s encephalopathy (WE):

Assess thiamine levels and nutritional status prior to starting therapy, periodically during therapy, and as indicated.
Do not initiate this drug in patients with thiamine deficiency; replete thiamine prior to therapy initiation and during therapy if thiamine levels are low.
If Wernicke’s encephalopathy is suspected, immediately discontinue therapy and initiate parenteral thiamine treatment.
Monitor until symptoms resolve or improve and thiamine levels normalize.

Dose Adjustments

Discontinue therapy in patients unable to tolerate 200 mg daily. Consider dose reductions in patients who become transfusion-dependent during therapy with this drug.

DOSE MODIFICATIONS WITH CONCOMITANT USE OF STRONG CYP450 3A4 INHIBITORS:

Reduce the dose of this drug when administering with strong CYP450 3A4 inhibitors to 200 mg orally once a day.
If the strong CYP450 3A4 inhibitor is discontinued, increase the dose of this drug to 300 mg orally once d day during the first 2 weeks after discontinuation of the CYP450 3A4 inhibitor, and then to 400 mg orally once a day thereafter as tolerated.

DOSE MODIFICATIONS FOR HEMATOLOGIC ADVERSE REACTIONS:

Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with active bleeding: Withhold therapy until resolved to Grade 2 or less or baseline; restart at 100 mg daily below the last given dose.
Grade 4 Neutropenia: Withhold therapy until resolved to Grade 2 or less or baseline, restart dose at 100 mg daily below the last given dose.

`DOSE MODIFICATIONS FOR NONHEMATOLOGIC ADVERSE REACTIONS:

Grade 3 or higher nausea, vomiting, or diarrhea not responding to supportive measures within 48 hours: Withhold therapy until resolved to Grade 1 or less or baseline; restart dose at 100 mg daily below the last given dose.
Grade 3 or higher ALT, AST, or bilirubin: Withhold therapy until resolved to Grade 1 or less or baseline; restart dose at 100 mg daily below the last given dose; monitor ALT, AST, and bilirubin (total and direct) more frequently following the dose reduction; if reoccurrence of Grade 3 or higher elevation, discontinue therapy.
Grade 3 or higher other nonhematologic toxicities: Withhold therapy until resolved to Grade 1 or less or baseline; restart dose at 100 mg daily below the last given dose.

Administration advice:

This drug may be taken with or without food.
Administration of a high-fat meal may reduce the incidence of nausea and vomiting.
If a dose is missed, the next scheduled dose should be taken the following day.
Patients taking ruxolitinib before initiation of this drug should taper and discontinue according to the ruxolitinib prescribing information.

Side Effects

The Most Common

nausea
vomiting
diarrhea
constipation
tiredness
muscle spasms
arm, leg, or bone pain
headache
weight gain
dizziness
unusual bleeding or bruising
fever, chills, cough, painful or frequent urination, or other signs of infection
nausea, extreme tiredness, unusual bruising or bleeding, lack of energy, loss of appetite, pain in the upper right part of the stomach, yellowing of the skin or eyes, or flu-like symptoms
shortness of breath, fast heartbeat, headache, dizziness, pale skin, confusion, or tiredness
pain in the chest, arms, back, neck, jaw, or stomach; breaking out in cold sweat; lightheadedness
slow or difficult speech; sudden weakness or numbness of the face, arm or leg; sudden headache; sudden vision problems; sudden difficulty walking
swelling, pain, tenderness, warmth or redness in one or both legs
shortness of breath, coughing up blood, fast heartbeat, fast breathing, pain when breathing deeply

More common

Black, tarry stools
bleeding gums
blood in the urine or stools
chills
cough
fever
lower back or side pain
painful or difficult urination
pale skin
pinpoint red spots on the skin
sore throat
troubled breathing with exertion
ulcers, sores, or white spots in the mouth
unusual bleeding or bruising
unusual tiredness or weakness
Bone pain
diarrhea
dizziness
headache
lack or loss of strength
muscle spasms
nausea
pain in the arms or legs
vomiting
weight gain

Rare

Bladder pain
cloudy urine
confusion
difficult, burning, or painful urination
drowsiness
frequent urge to urinate
lower back or side pain
shakiness and unsteady walk
trouble remembering
uncontrolled eye movements
unsteadiness, trembling, or other problems with muscle control or coordination

Drug Interactions

DRUG	INTERACTION
Abaloparatide	The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Fedratinib.
Abametapir	The serum concentration of Fedratinib can be increased when it is combined with Abametapir.
Abatacept	The metabolism of Fedratinib can be increased when combined with Abatacept.
Abemaciclib	The serum concentration of Abemaciclib can be increased when it is combined with Fedratinib.
Abrocitinib	The serum concentration of Fedratinib can be increased when it is combined with Abrocitinib.
Acebutolol	The metabolism of Acebutolol can be decreased when combined with Fedratinib.
Acenocoumarol	The metabolism of Fedratinib can be decreased when combined with Acenocoumarol.
Acetaminophen	The serum concentration of Acetaminophen can be increased when it is combined with Fedratinib.
Acyclovir	The excretion of Acyclovir can be decreased when combined with Fedratinib.
Adalimumab	The metabolism of Fedratinib can be increased when combined with Adalimumab.
Afatinib	The serum concentration of Afatinib can be increased when it is combined with Fedratinib.
Albendazole	The metabolism of Fedratinib can be decreased when combined with Albendazole.
Allopurinol	Fedratinib may decrease the excretion rate of Allopurinol which could result in a higher serum level.
Almotriptan	The metabolism of Almotriptan can be decreased when combined with Fedratinib.
Alogliptin	The metabolism of Alogliptin can be decreased when combined with Fedratinib.
Alpelisib	The serum concentration of Alpelisib can be increased when it is combined with Fedratinib.
Ambrisentan	The serum concentration of Ambrisentan can be increased when it is combined with Fedratinib.
Aminophenazone	The metabolism of Aminophenazone can be decreased when combined with Fedratinib.
Amiodarone	The metabolism of Fedratinib can be decreased when combined with Amiodarone.
Amitriptyline	The metabolism of Amitriptyline can be decreased when combined with Fedratinib.
Amoxapine	The metabolism of Amoxapine can be decreased when combined with Fedratinib.
Amphetamine	The metabolism of Amphetamine can be decreased when combined with Fedratinib.
Amprenavir	The metabolism of Fedratinib can be decreased when combined with Amprenavir.
Anakinra	The metabolism of Fedratinib can be increased when combined with Anakinra.
Antipyrine	The metabolism of Antipyrine can be decreased when combined with Fedratinib.
Apalutamide	The serum concentration of Fedratinib can be increased when it is combined with Apalutamide.
Apixaban	Fedratinib may decrease the excretion rate of Apixaban which could result in a higher serum level.
Apremilast	The metabolism of Fedratinib can be increased when combined with Apremilast.
Aprepitant	The metabolism of Fedratinib can be decreased when combined with Aprepitant.
Arformoterol	The metabolism of Arformoterol can be decreased when combined with Fedratinib.
Aripiprazole	The metabolism of Aripiprazole can be decreased when combined with Fedratinib.
Aripiprazole lauroxil	The metabolism of Aripiprazole lauroxil can be decreased when combined with Fedratinib.
Armodafinil	The metabolism of Fedratinib can be decreased when combined with Armodafinil.
Arsenic trioxide	The serum concentration of Fedratinib can be increased when it is combined with Arsenic trioxide.
Artemether	The metabolism of Fedratinib can be decreased when combined with Artemether.
Artenimol	The metabolism of Fedratinib can be decreased when combined with Artenimol.
Articaine	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Articaine.
Asciminib	The serum concentration of Fedratinib can be increased when it is combined with Asciminib.
Astemizole	The metabolism of Astemizole can be decreased when combined with Fedratinib.
Asunaprevir	The serum concentration of Fedratinib can be increased when it is combined with Asunaprevir.
Atazanavir	The metabolism of Fedratinib can be decreased when combined with Atazanavir.
Atenolol	The metabolism of Atenolol can be decreased when combined with Fedratinib.
Atogepant	The serum concentration of Atogepant can be increased when it is combined with Fedratinib.
Atomoxetine	The metabolism of Atomoxetine can be decreased when combined with Fedratinib.
Atorvastatin	The excretion of Atorvastatin can be decreased when combined with Fedratinib.
Avanafil	The serum concentration of Avanafil can be increased when it is combined with Fedratinib.
Avatrombopag	The serum concentration of Avatrombopag can be increased when it is combined with Fedratinib.
Axitinib	The serum concentration of Axitinib can be increased when it is combined with Fedratinib.
Azelastine	The metabolism of Azelastine can be decreased when combined with Fedratinib.
Baricitinib	The excretion of Baricitinib can be decreased when combined with Fedratinib.
Belantamab	The serum concentration of Belantamab mafodotin can be increased when it is combined with Fedratinib.
Belinostat	The serum concentration of Belinostat can be increased when it is combined with Fedratinib.
Belumosudil	The serum concentration of Fedratinib can be increased when it is combined with Belumosudil.
Belzutifan	The metabolism of Belzutifan can be decreased when combined with Fedratinib.
Bempedoic acid	The excretion of Bempedoic acid can be decreased when combined with Fedratinib.
Bendamustine	The serum concentration of Bendamustine can be increased when it is combined with Fedratinib.
Benzatropine	The metabolism of Benzatropine can be decreased when combined with Fedratinib.
Benzocaine	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Benzocaine.
Benzyl alcohol	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Benzyl alcohol.
Benzylpenicillin	The excretion of Benzylpenicillin can be decreased when combined with Fedratinib.
Bepridil	The metabolism of Bepridil can be decreased when combined with Fedratinib.
Berotralstat	The serum concentration of Berotralstat can be increased when it is combined with Fedratinib.
Betaxolol	The metabolism of Betaxolol can be decreased when combined with Fedratinib.
Betrixaban	The serum concentration of Betrixaban can be increased when it is combined with Fedratinib.
Bimekizumab	The metabolism of Fedratinib can be increased when combined with Bimekizumab.
Binimetinib	The serum concentration of Binimetinib can be increased when it is combined with Fedratinib.
Bisoprolol	The serum concentration of Bisoprolol can be increased when it is combined with Fedratinib.
Boceprevir	The metabolism of Fedratinib can be decreased when combined with Boceprevir.
Bortezomib	The serum concentration of Bortezomib can be increased when it is combined with Fedratinib.
Bosentan	The excretion of Bosentan can be decreased when combined with Fedratinib.
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Fedratinib.
Brentuximab	The serum concentration of Brentuximab vedotin can be increased when it is combined with Fedratinib.
Brexpiprazole	The metabolism of Brexpiprazole can be decreased when combined with Fedratinib.
Brigatinib	Fedratinib may decrease the excretion rate of Brigatinib which could result in a higher serum level.
Brincidofovir	The serum concentration of Brincidofovir can be increased when it is combined with Fedratinib.
Bupivacaine	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Bupivacaine.
Buprenorphine	The metabolism of Fedratinib can be decreased when combined with Buprenorphine.
Buspirone	The metabolism of Buspirone can be decreased when combined with Fedratinib.
Butacaine	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Butacaine.
Butamben	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Butamben.
Cabazitaxel	The serum concentration of Cabazitaxel can be increased when it is combined with Fedratinib.
Cabergoline	The serum concentration of Cabergoline can be increased when it is combined with Fedratinib.
Canagliflozin	The serum concentration of Fedratinib can be increased when it is combined with Canagliflozin.
Canakinumab	The metabolism of Fedratinib can be increased when combined with Canakinumab.
Cannabidiol	The metabolism of Fedratinib can be decreased when combined with Cannabidiol.
Capmatinib	The serum concentration of Fedratinib can be increased when it is combined with Capmatinib.
Capsaicin	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Capsaicin.
Carbamazepine	The metabolism of Fedratinib can be increased when combined with Carbamazepine.
Carbimazole	The therapeutic efficacy of Carbimazole can be decreased when used in combination with Fedratinib.
Carfilzomib	The serum concentration of Carfilzomib can be increased when it is combined with Fedratinib.
Carisoprodol	The metabolism of Fedratinib can be decreased when combined with Carisoprodol.
Carvedilol	The serum concentration of Fedratinib can be increased when it is combined with Carvedilol.
Caspofungin	The excretion of Caspofungin can be decreased when combined with Fedratinib.
Cefradine	The excretion of Cefradine can be decreased when combined with Fedratinib.
Celecoxib	Fedratinib may decrease the excretion rate of Celecoxib which could result in a higher serum level.
Celiprolol	The metabolism of Celiprolol can be decreased when combined with Fedratinib.
Cenobamate	The serum concentration of Fedratinib can be decreased when it is combined with Cenobamate.
Cephalexin	The excretion of Cephalexin can be decreased when combined with Fedratinib.
Ceritinib	The serum concentration of Ceritinib can be increased when it is combined with Fedratinib.
Cerivastatin	Fedratinib may decrease the excretion rate of Cerivastatin which could result in a higher serum level.

Certolizumab	The metabolism of Fedratinib can be increased when combined with Certolizumab pegol.
Cevimeline	The metabolism of Cevimeline can be decreased when combined with Fedratinib.
Chloramphenicol	The metabolism of Fedratinib can be decreased when combined with Chloramphenicol.
Chloroprocaine	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Chloroprocaine.
Chloroquine	The metabolism of Chloroquine can be decreased when combined with Fedratinib.
Chlorpheniramine	The metabolism of Chlorpheniramine can be decreased when combined with Fedratinib.
Chlorpromazine	The metabolism of Chlorpromazine can be decreased when combined with Fedratinib.
Chlorzoxazone	The metabolism of Chlorzoxazone can be decreased when combined with Fedratinib.
Cholecystokinin	The excretion of Cholecystokinin can be decreased when combined with Fedratinib.
Cholic Acid	The excretion of Cholic Acid can be decreased when combined with Fedratinib.
Ciclesonide	The metabolism of Ciclesonide can be decreased when combined with Fedratinib.
Cilostazol	The metabolism of Cilostazol can be decreased when combined with Fedratinib.
Cimetidine	The metabolism of Fedratinib can be decreased when combined with Cimetidine.
Cinchocaine	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Cinchocaine.
Cinnarizine	The metabolism of Cinnarizine can be decreased when combined with Fedratinib.
Ciprofloxacin	The metabolism of Fedratinib can be decreased when combined with Ciprofloxacin.
Citalopram	The metabolism of Fedratinib can be decreased when combined with Citalopram.
Cladribine	Fedratinib may decrease the excretion rate of Cladribine which could result in a higher serum level.
Clarithromycin	The metabolism of Fedratinib can be decreased when combined with Clarithromycin.
Clevidipine	The metabolism of Fedratinib can be decreased when combined with Clevidipine.
Clobazam	The serum concentration of Clobazam can be increased when it is combined with Fedratinib.
Clofarabine	Fedratinib may decrease the excretion rate of Clofarabine which could result in a higher serum level.
Clofazimine	The serum concentration of Fedratinib can be increased when it is combined with Clofazimine.
Clomifene	The serum concentration of Clomifene can be increased when it is combined with Fedratinib.
Clomipramine	The metabolism of Clomipramine can be decreased when combined with Fedratinib.
Clonidine	The metabolism of Clonidine can be decreased when combined with Fedratinib.
Clopidogrel	The metabolism of Fedratinib can be decreased when combined with Clopidogrel.
Clozapine	The metabolism of Fedratinib can be decreased when combined with Clozapine.
Cobicistat	The metabolism of Fedratinib can be decreased when combined with Cobicistat.
Cobimetinib	The serum concentration of Cobimetinib can be increased when it is combined with Fedratinib.
Cocaine	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Cocaine.
Codeine	The metabolism of Codeine can be decreased when combined with Fedratinib.
Colchicine	The serum concentration of Colchicine can be increased when it is combined with Fedratinib.
Conivaptan	The metabolism of Fedratinib can be decreased when combined with Conivaptan.
Conjugated	Fedratinib may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level.
Copanlisib	The serum concentration of Copanlisib can be increased when it is combined with Fedratinib.
Crizotinib	The serum concentration of Crizotinib can be increased when it is combined with Fedratinib.
Curcumin	The metabolism of Fedratinib can be decreased when combined with Curcumin.
Cyclophosphamide	The metabolism of Fedratinib can be decreased when combined with Cyclophosphamide.
Cyclosporine	The serum concentration of Cyclosporine can be increased when it is combined with Fedratinib.
Dabigatran etexilate	The serum concentration of Dabigatran etexilate can be increased when it is combined with Fedratinib.
Dabrafenib	The serum concentration of Fedratinib can be decreased when it is combined with Dabrafenib.
Daclatasvir	The serum concentration of Fedratinib can be increased when it is combined with Daclatasvir.
Dacomitinib	The serum concentration of Dacomitinib can be increased when it is combined with Fedratinib.
Dactinomycin	The serum concentration of Dactinomycin can be increased when it is combined with Fedratinib.
Danazol	The metabolism of Fedratinib can be decreased when combined with Danazol.
Dapagliflozin	The metabolism of Dapagliflozin can be decreased when combined with Fedratinib.
Daptomycin	The serum concentration of Daptomycin can be increased when it is combined with Fedratinib.
Darbepoetin alfa	The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Fedratinib.
Darifenacin	The metabolism of Darifenacin can be decreased when combined with Fedratinib.
Darolutamide	Fedratinib may decrease the excretion rate of Darolutamide which could result in a higher serum level.
Darunavir	The metabolism of Fedratinib can be decreased when combined with Darunavir.
Dasabuvir	The serum concentration of Dasabuvir can be increased when it is combined with Fedratinib.
Dasatinib	The serum concentration of Dasatinib can be increased when it is combined with Fedratinib.
Daunorubicin	Fedratinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level.
Debrisoquine	The metabolism of Debrisoquine can be decreased when combined with Fedratinib.
Delafloxacin	Fedratinib may decrease the excretion rate of Delafloxacin which could result in a higher serum level.
Delavirdine	The metabolism of Fedratinib can be decreased when combined with Delavirdine.
Desipramine	The metabolism of Desipramine can be decreased when combined with Fedratinib.
Desvenlafaxine	The metabolism of Fedratinib can be decreased when combined with Desvenlafaxine.
Deutetrabenazine	The metabolism of Deutetrabenazine can be decreased when combined with Fedratinib.
Dexamethasone	The metabolism of Fedratinib can be increased when combined with Dexamethasone.
Dexchlorpheniramine	The metabolism of Dexchlorpheniramine maleate can be decreased when combined with Fedratinib.
Dexfenfluramine	The metabolism of Dexfenfluramine can be decreased when combined with Fedratinib.
Dexlansoprazole	The metabolism of Fedratinib can be decreased when combined with Dexlansoprazole.
Dextroamphetamine	The metabolism of Dextroamphetamine can be decreased when combined with Fedratinib.
Dextromethorphan	The metabolism of Dextromethorphan can be decreased when combined with Fedratinib.
Dextropropoxyphene	The metabolism of Dextropropoxyphene can be decreased when combined with Fedratinib.
Diazepam	The metabolism of Fedratinib can be decreased when combined with Diazepam.
Digitoxin	The serum concentration of Digitoxin can be increased when it is combined with Fedratinib.
Digoxin	Fedratinib may decrease the excretion rate of Digoxin which could result in a higher serum level.
Dihydrocodeine	The metabolism of Dihydrocodeine can be decreased when combined with Fedratinib.
Diltiazem	The metabolism of Fedratinib can be decreased when combined with Diltiazem.
Dimethyl sulfoxide	The metabolism of Fedratinib can be decreased when combined with Dimethyl sulfoxide.
Dinoprostone	The excretion of Dinoprostone can be decreased when combined with Fedratinib.
Diosmin	The serum concentration of Fedratinib can be increased when it is combined with Diosmin.
Diphenhydramine	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Diphenhydramine.
Docetaxel	The excretion of Docetaxel can be decreased when combined with Fedratinib.
Dolasetron	The metabolism of Dolasetron can be decreased when combined with Fedratinib.
Dolutegravir	Fedratinib may decrease the excretion rate of Dolutegravir which could result in a higher serum level.
Domperidone	The metabolism of Domperidone can be decreased when combined with Fedratinib.
Donepezil	Fedratinib may decrease the excretion rate of Donepezil which could result in a higher serum level.
Dosulepin	The metabolism of Dosulepin can be decreased when combined with Fedratinib.
Doxazosin	The metabolism of Fedratinib can be decreased when combined with Doxazosin.
Doxepin	The metabolism of Fedratinib can be decreased when combined with Doxepin.
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Fedratinib.
Dronabinol	The metabolism of Fedratinib can be decreased when combined with Dronabinol.
Dronedarone	The metabolism of Fedratinib can be decreased when combined with Dronedarone.
Duloxetine	The metabolism of Duloxetine can be decreased when combined with Fedratinib.
Duvelisib	Fedratinib may decrease the excretion rate of Duvelisib which could result in a higher serum level.
Dyclonine	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Dyclonine.
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Fedratinib.
Efavirenz	The metabolism of Fedratinib can be decreased when combined with Efavirenz.
Elagolix	The serum concentration of Fedratinib can be increased when it is combined with Elagolix.
Elbasvir	The serum concentration of Elbasvir can be increased when it is combined with Fedratinib.
Eletriptan	The metabolism of Eletriptan can be decreased when combined with Fedratinib.
Eliglustat	The serum concentration of Fedratinib can be increased when it is combined with Eliglustat.
Eluxadoline	The serum concentration of Eluxadoline can be increased when it is combined with Fedratinib.
Elvitegravir	The metabolism of Fedratinib can be decreased when combined with Elvitegravir.
Emapalumab	The metabolism of Fedratinib can be increased when combined with Emapalumab.

Emtricitabine	The excretion of Emtricitabine can be decreased when combined with Fedratinib.
Enalapril	The excretion of Enalapril can be decreased when combined with Fedratinib.
Enasidenib	The metabolism of Enasidenib can be decreased when combined with Fedratinib.
Encainide	The metabolism of Encainide can be decreased when combined with Fedratinib.
Encorafenib	The metabolism of Encorafenib can be decreased when combined with Fedratinib.
Enfortumab	The serum concentration of Enfortumab vedotin can be increased when it is combined with Fedratinib.
Entrectinib	The serum concentration of Fedratinib can be increased when it is combined with Entrectinib.
Enzalutamide	The serum concentration of Fedratinib can be decreased when it is combined with Enzalutamide.
Epinastine	The metabolism of Epinastine can be decreased when combined with Fedratinib.
Erdafitinib	The serum concentration of Fedratinib can be increased when it is combined with Erdafitinib.
Ergotamine	The metabolism of Fedratinib can be decreased when combined with Ergotamine.
Erlotinib	The metabolism of Erlotinib can be decreased when combined with Fedratinib.
Ertugliflozin	Fedratinib may decrease the excretion rate of Ertugliflozin which could result in a higher serum level.
Erythromycin	The metabolism of Fedratinib can be decreased when combined with Erythromycin.
Erythropoietin	The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Fedratinib.
Escitalopram	The metabolism of Fedratinib can be decreased when combined with Escitalopram.
Esketamine	The metabolism of Fedratinib can be decreased when combined with Esketamine.
Eslicarbazepine	The metabolism of Fedratinib can be decreased when combined with Eslicarbazepine.
Eslicarbazepine	The metabolism of Fedratinib can be decreased when combined with Eslicarbazepine acetate.
Esmolol	The metabolism of Esmolol can be decreased when combined with Fedratinib.
Esomeprazole	The metabolism of Fedratinib can be decreased when combined with Esomeprazole.
Estradiol	The metabolism of Fedratinib can be decreased when combined with Estradiol.
Estrone sulfate	The excretion of Estrone sulfate can be decreased when combined with Fedratinib.
Etanercept	The metabolism of Fedratinib can be increased when combined with Etanercept.
Ethambutol	The metabolism of Fedratinib can be decreased when combined with Ethambutol.
Ethanol	The metabolism of Fedratinib can be decreased when combined with Ethanol.
Ethinylestradiol	The metabolism of Fedratinib can be decreased when combined with Ethinylestradiol.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Ethyl chloride.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Etidocaine.
Etoposide	The serum concentration of Etoposide can be increased when it is combined with Fedratinib.
Etoricoxib	The metabolism of Fedratinib can be decreased when combined with Etoricoxib.
Etravirine	The metabolism of Fedratinib can be decreased when combined with Etravirine.
Everolimus	The serum concentration of Everolimus can be increased when it is combined with Fedratinib.
Ezetimibe	Fedratinib may decrease the excretion rate of Ezetimibe which could result in a higher serum level.
Favipiravir	The serum concentration of Fedratinib can be increased when it is combined with Favipiravir.
Felbamate	The metabolism of Fedratinib can be decreased when combined with Felbamate.
Fenfluramine	The metabolism of Fenfluramine can be decreased when combined with Fedratinib.
Fenofibrate	The metabolism of Fedratinib can be decreased when combined with Fenofibrate.
Fesoterodine	The metabolism of Fesoterodine can be decreased when combined with Fedratinib.
Fexinidazole	The metabolism of Fedratinib can be decreased when combined with Fexinidazole.
Fexofenadine	The serum concentration of Fexofenadine can be increased when it is combined with Fedratinib.
Flecainide	The metabolism of Flecainide can be decreased when combined with Fedratinib.
Flibanserin	The serum concentration of Fedratinib can be increased when it is combined with Flibanserin.
Fluconazole	The metabolism of Fedratinib can be decreased when combined with Fluconazole.
Flunarizine	The metabolism of Flunarizine can be decreased when combined with Fedratinib.
Fluorouracil	Fedratinib may decrease the excretion rate of Fluorouracil which could result in a higher serum level.
Fluoxetine	The metabolism of Fedratinib can be decreased when combined with Fluoxetine.
Fluvastatin	The metabolism of Fluvastatin can be decreased when combined with Fedratinib.
Fluvoxamine	The metabolism of Fedratinib can be decreased when combined with Fluvoxamine.
Folic acid	Fedratinib may decrease the excretion rate of Folic acid which could result in a higher serum level.
Follitropin	The therapeutic efficacy of Follitropin can be decreased when used in combination with Fedratinib.
Formoterol	The metabolism of Fedratinib can be decreased when combined with Formoterol.
Fosnetupitant	The metabolism of Fedratinib can be decreased when combined with Fosnetupitant.
Fosphenytoin	The metabolism of Fedratinib can be increased when combined with Fosphenytoin.
Fostemsavir	Fedratinib may decrease the excretion rate of Fostemsavir which could result in a higher serum level.
Fusidic acid	The metabolism of Fedratinib can be decreased when combined with Fusidic acid.
Futibatinib	The serum concentration of Futibatinib can be increased when it is combined with Fedratinib.
Gadoxetic acid	The excretion of Gadoxetic acid can be decreased when combined with Fedratinib.
Galantamine	The metabolism of Galantamine can be decreased when combined with Fedratinib.
Ganciclovir	The excretion of Ganciclovir can be decreased when combined with Fedratinib.
Gefitinib	Fedratinib may decrease the excretion rate of Gefitinib which could result in a higher serum level.
Gemcitabine	The serum concentration of Gemcitabine can be increased when it is combined with Fedratinib.
Gemfibrozil	The metabolism of Fedratinib can be decreased when combined with Gemfibrozil.
Gilteritinib	The serum concentration of Gilteritinib can be increased when it is combined with Fedratinib.
Glasdegib	Fedratinib may decrease the excretion rate of Glasdegib which could result in a higher serum level.
Glecaprevir	Fedratinib may decrease the excretion rate of Glecaprevir which could result in a higher serum level.
Gliclazide	The metabolism of Fedratinib can be decreased when combined with Gliclazide.
Glyburide	Fedratinib may decrease the excretion rate of Glyburide which could result in a higher serum level.
Golimumab	The metabolism of Fedratinib can be increased when combined with Golimumab.
Grazoprevir	The serum concentration of Grazoprevir can be increased when it is combined with Fedratinib.
Guanidine	The excretion of Guanidine can be decreased when combined with Fedratinib.
Haloperidol	The serum concentration of Haloperidol can be increased when it is combined with Fedratinib.
Hydrocodone	The metabolism of Hydrocodone can be decreased when combined with Fedratinib.
Hydroxychloroquine	The metabolism of Hydroxychloroquine can be decreased when combined with Fedratinib.
Ibrutinib	The metabolism of Ibrutinib can be decreased when combined with Fedratinib.
Idarubicin	The metabolism of Idarubicin can be decreased when combined with Fedratinib.
Idelalisib	Fedratinib may decrease the excretion rate of Idelalisib which could result in a higher serum level.
Iloperidone	The metabolism of Iloperidone can be decreased when combined with Fedratinib.
Imatinib	Fedratinib may decrease the excretion rate of Imatinib which could result in a higher serum level.
Imipramine	The serum concentration of Imipramine can be increased when it is combined with Fedratinib.
Indacaterol	The serum concentration of Indacaterol can be increased when it is combined with Fedratinib.
Indinavir	The metabolism of Fedratinib can be decreased when combined with Indinavir.
Infliximab	The metabolism of Fedratinib can be increased when combined with Infliximab.
Inotuzumab	The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Fedratinib.
Ipecac	The metabolism of Ipecac can be decreased when combined with Fedratinib.
Irinotecan	Fedratinib may decrease the excretion rate of Irinotecan which could result in a higher serum level.
Isavuconazole	The serum concentration of Fedratinib can be increased when it is combined with Isavuconazole.
Isavuconazonium	The serum concentration of Fedratinib can be increased when it is combined with Isavuconazonium.
Isoniazid	The metabolism of Fedratinib can be decreased when combined with Isoniazid.
Isradipine	The metabolism of Fedratinib can be decreased when combined with Isradipine.
Istradefylline	The serum concentration of Fedratinib can be increased when it is combined with Istradefylline.
Itraconazole	The metabolism of Fedratinib can be decreased when combined with Itraconazole.
Ivacaftor	The serum concentration of Fedratinib can be increased when it is combined with Ivacaftor.
Ivermectin	Fedratinib may decrease the excretion rate of Ivermectin which could result in a higher serum level.
Ivosidenib	The metabolism of Fedratinib can be increased when combined with Ivosidenib.
Ixabepilone	The serum concentration of Fedratinib can be increased when it is combined with Ixabepilone.
Ketoconazole	The metabolism of Fedratinib can be decreased when combined with Ketoconazole.
Labetalol	The metabolism of Fedratinib can be decreased when combined with Labetalol.
Lacosamide	The metabolism of Fedratinib can be decreased when combined with Lacosamide.
Lamivudine	Fedratinib may decrease the excretion rate of Lamivudine which could result in a higher serum level.

Lansoprazole	The metabolism of Fedratinib can be decreased when combined with Lansoprazole.
Lapatinib	The serum concentration of Fedratinib can be increased when it is combined with Lapatinib.
Larotrectinib	The serum concentration of Larotrectinib can be increased when it is combined with Fedratinib.
Lasmiditan	The serum concentration of Fedratinib can be increased when it is combined with Lasmiditan.
Ledipasvir	The serum concentration of Ledipasvir can be increased when it is combined with Fedratinib.
Lefamulin	Fedratinib may decrease the excretion rate of Lefamulin which could result in a higher serum level.
Leflunomide	Fedratinib may decrease the excretion rate of Leflunomide which could result in a higher serum level.
Lemborexant	The serum concentration of Lemborexant can be increased when it is combined with Fedratinib.
Lenvatinib	Fedratinib may decrease the excretion rate of Lenvatinib which could result in a higher serum level.
Letermovir	The metabolism of Fedratinib can be increased when combined with Letermovir.
Letrozole	The metabolism of Fedratinib can be decreased when combined with Letrozole.
Levobetaxolol	The metabolism of Levobetaxolol can be decreased when combined with Fedratinib.
Levobupivacaine	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Levobupivacaine.
Levofloxacin	The excretion of Levofloxacin can be decreased when combined with Fedratinib.
Levoketoconazole	The metabolism of Fedratinib can be decreased when combined with Levoketoconazole.
Levomilnacipran	The metabolism of Levomilnacipran can be decreased when combined with Fedratinib.
Levosalbutamol	The excretion of Levosalbutamol can be decreased when combined with Fedratinib.
Levothyroxine	The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Fedratinib.
Lidocaine	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Lidocaine.
Linagliptin	The metabolism of Fedratinib can be decreased when combined with Linagliptin.
Liothyronine	The therapeutic efficacy of Liothyronine can be decreased when used in combination with Fedratinib.
Liotrix	The therapeutic efficacy of Liotrix can be decreased when used in combination with Fedratinib.
Lisdexamfetamine	The metabolism of Lisdexamfetamine can be decreased when combined with Fedratinib.
Lisuride	The metabolism of Lisuride can be decreased when combined with Fedratinib.
Lofexidine	The metabolism of Lofexidine can be decreased when combined with Fedratinib.
Lomitapide	The serum concentration of Fedratinib can be increased when it is combined with Lomitapide.
Lonafarnib	The metabolism of Fedratinib can be decreased when combined with Lonafarnib.
Loncastuximab	The serum concentration of Loncastuximab tesirine can be increased when it is combined with Fedratinib.
Loperamide	The excretion of Loperamide can be decreased when combined with Fedratinib.
Lopinavir	The metabolism of Fedratinib can be decreased when combined with Lopinavir.
Lorcaserin	The metabolism of Lorcaserin can be decreased when combined with Fedratinib.
Lorpiprazole	The metabolism of Lorpiprazole can be decreased when combined with Fedratinib.
Losartan	The metabolism of Fedratinib can be decreased when combined with Losartan.
Lovastatin	The metabolism of Fedratinib can be decreased when combined with Lovastatin.
Loxapine	The serum concentration of Fedratinib can be increased when it is combined with Loxapine.
Luliconazole	The serum concentration of Fedratinib can be increased when it is combined with Luliconazole.
Lumacaftor	The serum concentration of Fedratinib can be decreased when it is combined with Lumacaftor.
Lusutrombopag	Fedratinib may decrease the excretion rate of Lusutrombopag which could result in a higher serum level.
Lynestrenol	The metabolism of Fedratinib can be decreased when combined with Lynestrenol.
Manidipine	The metabolism of Fedratinib can be decreased when combined with Manidipine.
Mannitol	The serum concentration of Mannitol can be increased when it is combined with Fedratinib.
Maprotiline	The metabolism of Maprotiline can be decreased when combined with Fedratinib.
Maribavir	The serum concentration of Fedratinib can be increased when it is combined with Maribavir.
Mavacamten	The serum concentration of Fedratinib can be decreased when it is combined with Mavacamten.
Meclizine	The metabolism of Meclizine can be decreased when combined with Fedratinib.
Mefloquine	The serum concentration of Fedratinib can be increased when it is combined with Mefloquine.
Meloxicam	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Meloxicam.
Memantine	The metabolism of Fedratinib can be decreased when combined with Memantine.
Mephenytoin	The metabolism of Fedratinib can be decreased when combined with Mephenytoin.
Mepivacaine	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Mepivacaine.
Mesoridazine	The metabolism of Mesoridazine can be decreased when combined with Fedratinib.
Metamfetamine	The metabolism of Metamfetamine can be decreased when combined with Fedratinib.
Metformin	The excretion of Metformin can be decreased when combined with Fedratinib.
Methadone	The metabolism of Fedratinib can be decreased when combined with Methadone.
Methimazole	The metabolism of Fedratinib can be decreased when combined with Methimazole.
Methotrexate	Fedratinib may decrease the excretion rate of Methotrexate which could result in a higher serum level.
Methotrimeprazine	The metabolism of Methotrimeprazine can be decreased when combined with Fedratinib.
Methoxy	The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Fedratinib.
Methoxyflurane	The metabolism of Methoxyflurane can be decreased when combined with Fedratinib.
Methsuximide	The metabolism of Fedratinib can be decreased when combined with Methsuximide.
Methylene blue	The serum concentration of Fedratinib can be increased when it is combined with Methylene blue.
Methylphenobar	The metabolism of Fedratinib can be decreased when combined with Methylphenobarbital.
Metoclopramide	The metabolism of Metoclopramide can be decreased when combined with Fedratinib.
Metoprolol	The metabolism of Metoprolol can be decreased when combined with Fedratinib.
Metreleptin	The metabolism of Fedratinib can be increased when combined with Metreleptin.
Mexiletine	The metabolism of Mexiletine can be decreased when combined with Fedratinib.
Mianserin	The metabolism of Mianserin can be decreased when combined with Fedratinib.
Miconazole	The metabolism of Fedratinib can be decreased when combined with Miconazole.
Midostaurin	The metabolism of Fedratinib can be decreased when combined with Midostaurin.
Mifepristone	The serum concentration of Fedratinib can be increased when it is combined with Mifepristone.
Milnacipran	The metabolism of Fedratinib can be decreased when combined with Milnacipran.
Minaprine	The metabolism of Minaprine can be decreased when combined with Fedratinib.
Mirabegron	The serum concentration of Fedratinib can be increased when it is combined with Mirabegron.
Mirtazapine	The metabolism of Mirtazapine can be decreased when combined with Fedratinib.
Mitapivat	The serum concentration of Fedratinib can be increased when it is combined with Mitapivat.
Mitotane	The metabolism of Fedratinib can be increased when combined with Mitotane.
Mitoxantrone	Fedratinib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level.
Moclobemide	The metabolism of Fedratinib can be decreased when combined with Moclobemide.
Modafinil	The metabolism of Fedratinib can be decreased when combined with Modafinil.
Morphine	The serum concentration of Morphine can be increased when it is combined with Fedratinib.
Mycophenolate	Fedratinib may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level.
Nadolol	The metabolism of Nadolol can be decreased when combined with Fedratinib.
Naloxegol	The serum concentration of Naloxegol can be increased when it is combined with Fedratinib.
Naloxone	The metabolism of Fedratinib can be decreased when combined with Naloxone.
Nateglinide	The metabolism of Nateglinide can be decreased when combined with Fedratinib.
Nebivolol	The metabolism of Fedratinib can be decreased when combined with Nebivolol.
Nefazodone	The metabolism of Fedratinib can be decreased when combined with Nefazodone.
Nelfinavir	The metabolism of Fedratinib can be decreased when combined with Nelfinavir.
Neratinib	The serum concentration of Fedratinib can be increased when it is combined with Neratinib.
Netupitant	The metabolism of Fedratinib can be decreased when combined with Netupitant.
Nevirapine	The metabolism of Nevirapine can be decreased when combined with Fedratinib.
Nicardipine	The metabolism of Fedratinib can be decreased when combined with Nicardipine.
Nicergoline	The metabolism of Nicergoline can be decreased when combined with Fedratinib.
Nifedipine	The metabolism of Nifedipine can be decreased when combined with Fedratinib.
Nilotinib	The metabolism of Fedratinib can be decreased when combined with Nilotinib.
Nilutamide	The metabolism of Fedratinib can be decreased when combined with Nilutamide.
Nilvadipine	The metabolism of Fedratinib can be decreased when combined with Nilvadipine.
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Fedratinib.
Nitrofurantoin	Fedratinib may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.
Norgestimate	The serum concentration of Fedratinib can be increased when it is combined with Norgestimate.

Nortriptyline	The serum concentration of Nortriptyline can be increased when it is combined with Fedratinib.
Olanzapine	The metabolism of Fedratinib can be decreased when combined with Olanzapine.
Oliceridine	The metabolism of Oliceridine can be decreased when combined with Fedratinib.
Omadacycline	The serum concentration of Omadacycline can be increased when it is combined with Fedratinib.
Ombitasvir	Fedratinib may decrease the excretion rate of Ombitasvir which could result in a higher serum level.
Omeprazole	The metabolism of Fedratinib can be decreased when combined with Omeprazole.
Ondansetron	The metabolism of Ondansetron can be decreased when combined with Fedratinib.
Opium	The metabolism of Opium can be decreased when combined with Fedratinib.
Oritavancin	The metabolism of Fedratinib can be decreased when combined with Oritavancin.
Osilodrostat	The metabolism of Fedratinib can be decreased when combined with Osilodrostat.
Osimertinib	The serum concentration of Osimertinib can be increased when it is combined with Fedratinib.
Ouabain	The excretion of Ouabain can be decreased when combined with Fedratinib.
Oxaliplatin	Fedratinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level.
Oxcarbazepine	The metabolism of Fedratinib can be decreased when combined with Oxcarbazepine.
Oxetacaine	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Oxetacaine.
Oxprenolol	The metabolism of Oxprenolol can be decreased when combined with Fedratinib.
Oxybuprocaine	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Oxybuprocaine.
Oxycodone	The metabolism of Oxycodone can be decreased when combined with Fedratinib.
Oxymorphone	The metabolism of Oxymorphone can be decreased when combined with Fedratinib.
Ozanimod	Fedratinib may decrease the excretion rate of Ozanimod which could result in a higher serum level.
Paclitaxel	The excretion of Paclitaxel can be decreased when combined with Fedratinib.
Pacritinib	The serum concentration of Fedratinib can be increased when it is combined with Pacritinib.
Palbociclib	Fedratinib may decrease the excretion rate of Palbociclib which could result in a higher serum level.
Paliperidone	The serum concentration of Fedratinib can be increased when it is combined with Paliperidone.
Palonosetron	The metabolism of Palonosetron can be decreased when combined with Fedratinib.
Panobinostat	The serum concentration of Panobinostat can be increased when it is combined with Fedratinib.
Pantoprazole	The metabolism of Fedratinib can be decreased when combined with Pantoprazole.
Parathyroid	The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Fedratinib.
Paritaprevir	The serum concentration of Paritaprevir can be increased when it is combined with Fedratinib.
Paroxetine	The metabolism of Fedratinib can be decreased when combined with Paroxetine.
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Fedratinib.
Peginesatide	The risk or severity of Thrombosis can be increased when Peginesatide is combined with Fedratinib.
Penbutolol	The metabolism of Penbutolol can be decreased when combined with Fedratinib.
Penicillamine	The excretion of Penicillamine can be decreased when combined with Fedratinib.
Pentamidine	The metabolism of Fedratinib can be decreased when combined with Pentamidine.
Pentobarbital	The metabolism of Fedratinib can be increased when combined with Pentobarbital.
Perhexiline	The metabolism of Perhexiline can be decreased when combined with Fedratinib.
Perphenazine	The metabolism of Perphenazine can be decreased when combined with Fedratinib.
Phenformin	The metabolism of Phenformin can be decreased when combined with Fedratinib.
Phenobarbital	The metabolism of Fedratinib can be increased when combined with Phenobarbital.
Phenol	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Phenol.
Phenytoin	The metabolism of Fedratinib can be increased when combined with Phenytoin.
Pibrentasvir	Fedratinib may decrease the excretion rate of Pibrentasvir which could result in a higher serum level.
Pimozide	The metabolism of Pimozide can be decreased when combined with Fedratinib.
Pindolol	The metabolism of Pindolol can be decreased when combined with Fedratinib.
Piperazine	The metabolism of Piperazine can be decreased when combined with Fedratinib.
Pipotiazine	The metabolism of Pipotiazine can be decreased when combined with Fedratinib.
Pirfenidone	The metabolism of Fedratinib can be decreased when combined with Pirfenidone.
Pitavastatin	Fedratinib may decrease the excretion rate of Pitavastatin which could result in a higher serum level.
Pitolisant	The serum concentration of Fedratinib can be decreased when it is combined with Pitolisant.
Pomalidomide	The serum concentration of Pomalidomide can be increased when it is combined with Fedratinib.
Ponatinib	The metabolism of Ponatinib can be decreased when combined with Fedratinib.
Posaconazole	The metabolism of Fedratinib can be decreased when combined with Posaconazole.
Potassium Iodide	The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Fedratinib.
Potassium	The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Fedratinib.
Practolol	The metabolism of Practolol can be decreased when combined with Fedratinib.
Pralatrexate	Fedratinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level.
Pralsetinib	The serum concentration of Pralsetinib can be increased when it is combined with Fedratinib.
Pramocaine	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Pramocaine.
Pravastatin	Fedratinib may decrease the excretion rate of Pravastatin which could result in a higher serum level.
Praziquantel	The metabolism of Fedratinib can be decreased when combined with Praziquantel.
Prazosin	Fedratinib may decrease the excretion rate of Prazosin which could result in a higher serum level.
Prednisolone	The serum concentration of Prednisolone phosphate can be increased when it is combined with Fedratinib.
Prilocaine	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Prilocaine.
Primaquine	The metabolism of Fedratinib can be decreased when combined with Primaquine.
Primidone	The metabolism of Fedratinib can be increased when combined with Primidone.
Procainamide	The metabolism of Procainamide can be decreased when combined with Fedratinib.
Procaine	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Procaine.
Prochlorperazine	The metabolism of Prochlorperazine can be decreased when combined with Fedratinib.
Progesterone	The metabolism of Fedratinib can be decreased when combined with Progesterone.
Proguanil	The metabolism of Fedratinib can be decreased when combined with Proguanil.
Promazine	The metabolism of Promazine can be decreased when combined with Fedratinib.
Promethazine	The metabolism of Promethazine can be decreased when combined with Fedratinib.
Propafenone	The serum concentration of Fedratinib can be increased when it is combined with Propafenone.
Proparacaine	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Proparacaine.
Propoxycaine	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Propoxycaine.
Propranolol	The metabolism of Fedratinib can be decreased when combined with Propranolol.
Propylthiouracil	The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Fedratinib.
Protirelin	The therapeutic efficacy of Protirelin can be decreased when used in combination with Fedratinib.
Prucalopride	The serum concentration of Prucalopride can be increased when it is combined with Fedratinib.
Quetiapine	The metabolism of Quetiapine can be decreased when combined with Fedratinib.
Quinidine	The serum concentration of Quinidine can be increased when it is combined with Fedratinib.
Quinine	The serum concentration of Fedratinib can be increased when it is combined with Quinine.
Rabeprazole	The metabolism of Fedratinib can be decreased when combined with Rabeprazole.
Raloxifene	Fedratinib may decrease the excretion rate of Raloxifene which could result in a higher serum level.
Ramelteon	The metabolism of Fedratinib can be decreased when combined with Ramelteon.
Ranolazine	The serum concentration of Ranolazine can be increased when it is combined with Fedratinib.
Regorafenib	The serum concentration of Regorafenib can be increased when it is combined with Fedratinib.
Relebactam	The excretion of Relebactam can be decreased when combined with Fedratinib.
Relugolix	The serum concentration of Relugolix can be increased when it is combined with Fedratinib.
Remoxipride	The metabolism of Remoxipride can be decreased when combined with Fedratinib.
Repaglinide	The excretion of Repaglinide can be decreased when combined with Fedratinib.
Reserpine	The serum concentration of Fedratinib can be increased when it is combined with Reserpine.
Revefenacin	Fedratinib may decrease the excretion rate of Revefenacin which could result in a higher serum level.
Ribociclib	The metabolism of Fedratinib can be decreased when combined with Ribociclib.
Rifabutin	The metabolism of Fedratinib can be increased when combined with Rifabutin.
Rifampicin	The metabolism of Fedratinib can be increased when combined with Rifampicin.
Rifamycin	The metabolism of Fedratinib can be increased when combined with Rifamycin.
Rifapentine	The metabolism of Fedratinib can be increased when combined with Rifapentine.
Rifaximin	The serum concentration of Rifaximin can be increased when it is combined with Fedratinib.

Rilonacept	The metabolism of Fedratinib can be increased when combined with Rilonacept.
Rilpivirine	The metabolism of Fedratinib can be decreased when combined with Rilpivirine.
Riluzole	Fedratinib may decrease the excretion rate of Riluzole which could result in a higher serum level.
Rimegepant	The serum concentration of Rimegepant can be increased when it is combined with Fedratinib.
Riociguat	Fedratinib may decrease the excretion rate of Riociguat which could result in a higher serum level.
Ripretinib	Fedratinib may decrease the excretion rate of Ripretinib which could result in a higher serum level.
Risperidone	The metabolism of Risperidone can be decreased when combined with Fedratinib.
Ritonavir	The serum concentration of Fedratinib can be increased when it is combined with Ritonavir.
Rivaroxaban	Fedratinib may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
Rolapitant	The serum concentration of Fedratinib can be increased when it is combined with Rolapitant.
Romidepsin	The serum concentration of Romidepsin can be increased when it is combined with Fedratinib.
Ropivacaine	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Ropivacaine.
Rosuvastatin	Fedratinib may decrease the excretion rate of Rosuvastatin which could result in a higher serum level.
Rotigotine	The metabolism of Rotigotine can be decreased when combined with Fedratinib.
Rucaparib	Fedratinib may decrease the excretion rate of Rucaparib which could result in a higher serum level.
Rupatadine	The metabolism of Rupatadine can be decreased when combined with Fedratinib.
Salmon	The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Fedratinib.
Sapropterin	The serum concentration of Fedratinib can be increased when it is combined with Sapropterin.
Saquinavir	The metabolism of Fedratinib can be decreased when combined with Saquinavir.
Sarecycline	The serum concentration of Fedratinib can be increased when it is combined with Sarecycline.
Satralizumab	The serum concentration of Fedratinib can be decreased when it is combined with Satralizumab.
Secukinumab	The metabolism of Fedratinib can be increased when combined with Secukinumab.
Selegiline	The metabolism of Selegiline can be decreased when combined with Fedratinib.
Selexipag	The serum concentration of Selexipag can be increased when it is combined with Fedratinib.
Selumetinib	Fedratinib may decrease the excretion rate of Selumetinib which could result in a higher serum level.
Sertindole	The metabolism of Sertindole can be decreased when combined with Fedratinib.
Sertraline	The metabolism of Fedratinib can be decreased when combined with Sertraline.
Sildenafil	The serum concentration of Fedratinib can be increased when it is combined with Sildenafil.
Silodosin	The excretion of Silodosin can be decreased when combined with Fedratinib.
Siltuximab	The metabolism of Fedratinib can be increased when combined with Siltuximab.
Simeprevir	The metabolism of Fedratinib can be decreased when combined with Simeprevir.
Simvastatin	The serum concentration of Fedratinib can be increased when it is combined with Simvastatin.
Sincalide	The excretion of Sincalide can be decreased when combined with Fedratinib.
Sirolimus	The serum concentration of Sirolimus can be increased when it is combined with Fedratinib.
Sitagliptin	The serum concentration of Sitagliptin can be increased when it is combined with Fedratinib.
Sitaxentan	The metabolism of Fedratinib can be decreased when combined with Sitaxentan.
Sofosbuvir	Fedratinib may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.
Solifenacin	The metabolism of Solifenacin can be decreased when combined with Fedratinib.
Solriamfetol	The excretion of Solriamfetol can be decreased when combined with Fedratinib.
Somapacitan	The metabolism of Fedratinib can be decreased when combined with Somapacitan.
Somatrogon	The metabolism of Fedratinib can be increased when combined with Somatrogon.
Sorafenib	Fedratinib may decrease the excretion rate of Sorafenib which could result in a higher serum level.
Sotagliflozin	The serum concentration of Fedratinib can be increased when it is combined with Sotagliflozin.
Sotalol	The metabolism of Sotalol can be decreased when combined with Fedratinib.
Sotorasib	The serum concentration of Fedratinib can be decreased when it is combined with Sotorasib.
St. John’s Wort	The metabolism of Fedratinib can be increased when combined with St. John’s Wort.
Stiripentol	The metabolism of Fedratinib can be decreased when combined with Stiripentol.
Sulfasalazine	Fedratinib may decrease the excretion rate of Sulfasalazine which could result in a higher serum level.
Sumatriptan	Fedratinib may decrease the excretion rate of Sumatriptan which could result in a higher serum level.
Suvorexant	The serum concentration of Fedratinib can be increased when it is combined with Suvorexant.
Tacrolimus	The serum concentration of Fedratinib can be increased when it is combined with Tacrolimus.
Tafenoquine	The metabolism of Tafenoquine can be decreased when combined with Fedratinib.
Talazoparib	The serum concentration of Talazoparib can be increased when it is combined with Fedratinib.
Tamoxifen	The metabolism of Tamoxifen can be decreased when combined with Fedratinib.
Tamsulosin	The metabolism of Tamsulosin can be decreased when combined with Fedratinib.
Taurocholic acid	The excretion of Taurocholic acid can be decreased when combined with Fedratinib.
Tazemetostat	Fedratinib may decrease the excretion rate of Tazemetostat which could result in a higher serum level.
Technetium	The excretion of Technetium Tc-99m mebrofenin can be decreased when combined with Fedratinib.
Technetium	The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Fedratinib.
Tecovirimat	The metabolism of Fedratinib can be decreased when combined with Tecovirimat.
Tegaserod	Fedratinib may decrease the excretion rate of Tegaserod which could result in a higher serum level.
Telaprevir	The metabolism of Fedratinib can be decreased when combined with Telaprevir.
Telithromycin	The metabolism of Fedratinib can be decreased when combined with Telithromycin.
Telmisartan	The metabolism of Fedratinib can be decreased when combined with Telmisartan.
Telotristat ethyl	The serum concentration of Fedratinib can be decreased when it is combined with Telotristat ethyl.
Temsirolimus	The serum concentration of Temsirolimus can be increased when it is combined with Fedratinib.
Teniposide	Fedratinib may decrease the excretion rate of Teniposide which could result in a higher serum level.
Tenofovir	The serum concentration of Tenofovir alafenamide can be increased when it is combined with Fedratinib.
Tenofovir	The serum concentration of Tenofovir disoproxil can be increased when it is combined with Fedratinib.
Tepotinib	The serum concentration of Tepotinib can be increased when it is combined with Fedratinib.
Terfenadine	The metabolism of Fedratinib can be decreased when combined with Terfenadine.
Teriflunomide	Fedratinib may decrease the excretion rate of Teriflunomide which could result in a higher serum level.
Teriparatide	The therapeutic efficacy of Teriparatide can be decreased when used in combination with Fedratinib.
Testosterone	Fedratinib may decrease the excretion rate of Testosterone which could result in a higher serum level.
Testosterone	Fedratinib may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level.
Testosterone	Fedratinib may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level.
Tetrabenazine	The metabolism of Tetrabenazine can be decreased when combined with Fedratinib.
Tetracaine	The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Tetracaine.
Tezacaftor	The serum concentration of Tezacaftor can be increased when it is combined with Fedratinib.
Theophylline	The metabolism of Theophylline can be decreased when combined with Fedratinib.
Thiopental	The metabolism of Fedratinib can be decreased when combined with Thiopental.
Thioridazine	The metabolism of Fedratinib can be decreased when combined with Thioridazine.
Thyroid, porcine	The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Fedratinib.
Thyrotropin alfa	The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Fedratinib.
Ticagrelor	The serum concentration of Fedratinib can be increased when it is combined with Ticagrelor.
Ticlopidine	The metabolism of Fedratinib can be decreased when combined with Ticlopidine.
Timolol	The metabolism of Timolol can be decreased when combined with Fedratinib.
Tiotropium	The metabolism of Tiotropium can be decreased when combined with Fedratinib.
Tipranavir	The metabolism of Fedratinib can be decreased when combined with Tipranavir.
Tivozanib	The serum concentration of Tivozanib can be increased when it is combined with Fedratinib.
Tocilizumab	The metabolism of Fedratinib can be increased when combined with Tocilizumab.
Tolterodine	The metabolism of Tolterodine can be decreased when combined with Fedratinib.
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Fedratinib.
Topiramate	The metabolism of Fedratinib can be decreased when combined with Topiramate.
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Fedratinib.
Torasemide	The excretion of Torasemide can be decreased when combined with Fedratinib.
Toremifene	The serum concentration of Fedratinib can be increased when it is combined with Toremifene.
Trabectedin	The metabolism of Trabectedin can be decreased when combined with Fedratinib.
Tramadol	The metabolism of Tramadol can be decreased when combined with Fedratinib.
Tranylcypromine	The metabolism of Fedratinib can be decreased when combined with Tranylcypromine.

Trastuzumab	The serum concentration of Trastuzumab emtansine can be increased when it is combined with Fedratinib.
Trazodone	The metabolism of Trazodone can be decreased when combined with Fedratinib.
Triclabendazole	The metabolism of Fedratinib can be decreased when combined with Triclabendazole.
Trilaciclib	Fedratinib may decrease the excretion rate of Trilaciclib which could result in a higher serum level.
Trimethadione	The metabolism of Fedratinib can be decreased when combined with Trimethadione.
Trimipramine	The serum concentration of Trimipramine can be increased when it is combined with Fedratinib.
Troleandomycin	The metabolism of Fedratinib can be decreased when combined with Troleandomycin.
Tucatinib	Tucatinib may decrease the excretion rate of Fedratinib which could result in a higher serum level.
Ubrogepant	The serum concentration of Ubrogepant can be increased when it is combined with Fedratinib.
Umbralisib	The serum concentration of Fedratinib can be increased when it is combined with Umbralisib.
Umeclidinium	The serum concentration of Umeclidinium can be increased when it is combined with Fedratinib.
Valbenazine	The metabolism of Valbenazine can be decreased when combined with Fedratinib.
Valproic acid	The metabolism of Fedratinib can be decreased when combined with Valproic acid.
Valsartan	The excretion of Valsartan can be decreased when combined with Fedratinib.
Vandetanib	The serum concentration of Fedratinib can be increased when it is combined with Vandetanib.
Vardenafil	The serum concentration of Fedratinib can be increased when it is combined with Vardenafil.
Velpatasvir	Fedratinib may decrease the excretion rate of Velpatasvir which could result in a higher serum level.
Vemurafenib	The serum concentration of Fedratinib can be increased when it is combined with Vemurafenib.
Venetoclax	The serum concentration of Venetoclax can be increased when it is combined with Fedratinib.
Venlafaxine	The metabolism of Venlafaxine can be decreased when combined with Fedratinib.
Verapamil	The metabolism of Fedratinib can be decreased when combined with Verapamil.
Vernakalant	The metabolism of Vernakalant can be decreased when combined with Fedratinib.
Vilazodone	The metabolism of Fedratinib can be decreased when combined with Vilazodone.
Viloxazine	The metabolism of Fedratinib can be decreased when combined with Viloxazine.
Vinblastine	The serum concentration of Vinblastine can be increased when it is combined with Fedratinib.
Vincristine	The excretion of Vincristine can be decreased when combined with Fedratinib.
Vinflunine	The serum concentration of Vinflunine can be increased when it is combined with Fedratinib.
Voclosporin	The serum concentration of Fedratinib can be increased when it is combined with Voclosporin.
Vonoprazan	The metabolism of Fedratinib can be decreased when combined with Vonoprazan.
Vorapaxar	The serum concentration of Fedratinib can be increased when it is combined with Vorapaxar.
Voriconazole	The serum concentration of Fedratinib can be increased when it is combined with Voriconazole.
Vortioxetine	The metabolism of Fedratinib can be decreased when combined with Vortioxetine.
Voxelotor	The metabolism of Voxelotor can be decreased when combined with Fedratinib.
Voxilaprevir	Fedratinib may decrease the excretion rate of Voxilaprevir which could result in a higher serum level.
Yohimbine	The metabolism of Yohimbine can be decreased when combined with Fedratinib.
Zafirlukast	The metabolism of Fedratinib can be decreased when combined with Zafirlukast.
Zidovudine	Fedratinib may decrease the excretion rate of Zidovudine which could result in a higher serum level.
Zimelidine	The metabolism of Fedratinib can be decreased when combined with Zimelidine.
Ziprasidone	The metabolism of Fedratinib can be decreased when combined with Ziprasidone.
Zolpidem	The metabolism of Fedratinib can be decreased when combined with Zolpidem.
Zonisamide	The serum concentration of Fedratinib can be increased when it is combined with Zonisamide.
Zuclopenthixol	The metabolism of Zuclopenthixol can be decreased when combined with Fedratinib.

Pregnancy and Lactation

US FDA pregnancy category: Not assigned.

Pregnancy

This drug should be used during pregnancy only if the benefit outweighs the risk. Adequate methods of contraception should be encouraged. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.

Lactation

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.
Excreted into human milk: Unknown
Excreted into animal milk: Data not available
Because of the potential for serious adverse reactions in a breastfed child, advise patients not to breastfeed during therapy and for at least 1 month after.

How should this medicine be used?

Fedratinib comes as a capsule to take by mouth. It is usually taken once a day, with or without food. Taking fedratinib with a high fat meal may help to reduce nausea and vomiting. Take fedratinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take fedratinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Your doctor will order blood tests before and during your treatment to see how you are affected by this medication. Your doctor may increase or decrease your dose of fedratinib during your treatment, or may tell you to stop taking fedratinib temporarily or permanently. This depends on how well the medication works for you, your lab test results, and if you experience side effects. Talk to your doctor about how you are feeling during your treatment.

Other uses for this medicine

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

What special precautions should I follow?

Before taking fedratinib,

tell your doctor and pharmacist if you are allergic to fedratinib, any other medications, or any of the ingredients in fedratinib capsules. Ask your pharmacist or check the Medication Guide for a list of the ingredients.
tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: clarithromycin (Biaxin, in PrevPac), diltiazem (Cardizem, Dilacor, Tiazac, others), erythromycin (E.E.S., E-mycin, Erythrocin), idelalisib (Zydelig), indinavir (Crixivan), itraconazole (Sporanox), ketoconazole (Nizoral), metoprolol (Lopressor, Toprol XL, in Dutoprol, others), midazolam (Versed), nefazodone, nelfinavir (Viracept), omeprazole (Prilosec, in Zegerid), pantoprazole (Protonix), ribociclib (Kisqali, Kisqali, in Femera), ritonavir (Norvir), ruxolitinib (Jakafi), and saquinavir (Invirase). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with fedratinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
tell your doctor if you if you smoke or if you have ever smoked. Also tell your doctor if you have or have ever had cancer, pancreatitis (swelling of the pancreas), blood clots, a stroke, a heart attack or other heart problems, liver or kidney disease.
tell your doctor if you are pregnant or plan to become pregnant. If you become pregnant while taking fedratinib, call your doctor.
do not breastfeed during your treatment with fedratinib and for at least 1 month after your final dose.
if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking fedratinib.

References

https://www.cancer.gov/about-cancer/treatment/drugs/fedratinibhydrochloride
https://www.drugs.com/mtm/fedratinib.html
https://medlineplus.gov/druginfo/meds/a619058.html
https://go.drugbank.com/drugs/DB12500
https://en.wikipedia.org/wiki/Fedratinib
https://www.mayoclinic.org/drugs-supplements/fedratinib-oral-route/side-effects/drg-20469997https://www.mayoclinic.org/drugs-supplements/fedratinib-oral-route/side-effects/drg-20469997
https://pubchem.ncbi.nlm.nih.gov/compound/Fedratinib
https://pubchem.ncbi.nlm.nih.gov/compound/Fedratinib-dihydrochloride-monohydrate
https://www.webmd.com/drugs/2/drug-177751/fedratinib-oral/details/list-sideeffects
ChemIDplus

LICENSE

https://www.nlm.nih.gov/copyright.html

Fedratinib [USAN:INN]

https://chem.nlm.nih.gov/chemidplus/sid/0936091268

ChemIDplus Chemical Information Classification

https://chem.nlm.nih.gov/chemidplus/
DrugBank

https://www.drugbank.ca/legal/terms_of_use

Fedratinib

https://www.drugbank.ca/drugs/DB12500
EPA DSSTox

LICENSE

https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources

Fedratinib

https://comptox.epa.gov/dashboard/DTXSID90239483

CompTox Chemicals Dashboard Chemical Lists

https://comptox.epa.gov/dashboard/chemical-lists/
European Chemicals Agency (ECHA)

https://echa.europa.eu/web/guest/legal-notice

Fedratinib

https://echa.europa.eu/information-on-chemicals

Fedratinib

https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/273390
FDA Global Substance Registration System (GSRS)

https://www.fda.gov/about-fda/about-website/website-policies#linking

FEDRATINIB

https://gsrs.ncats.nih.gov/ginas/app/beta/substances/6L1XP550I6
ChEBI

http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:91408

ChEBI Ontology

http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology
LiverTox

LICENSE

https://www.nlm.nih.gov/copyright.html

Fedratinib

https://www.ncbi.nlm.nih.gov/books/n/livertox/Fedratinib/
NCI Thesaurus (NCIt)

https://www.cancer.gov/policies/copyright-reuse

https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C88293

NCI Thesaurus Tree

https://ncit.nci.nih.gov
ChEMBL

http://www.ebi.ac.uk/Information/termsofuse.html

https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1287853/

ChEMBL Protein Target Tree

https://www.ebi.ac.uk/chembl/g/#browse/targets
Chemical Probes Portal

Fedratinib

https://www.chemicalprobes.org/fedratinib
Comparative Toxicogenomics Database (CTD)

http://ctdbase.org/about/legal.jsp

fedratinib

https://ctdbase.org/detail.go?type=chem&acc=C528327
Drug Gene Interaction database (DGIdb)

http://www.dgidb.org/downloads

FEDRATINIB

https://www.dgidb.org/drugs/FEDRATINIB
IUPHAR/BPS Guide to PHARMACOLOGY

https://www.guidetopharmacology.org/about.jsp#license

fedratinib

https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5716

Guide to Pharmacology Target Classification

https://www.guidetopharmacology.org/targets.jsp
Therapeutic Target Database (TTD)

Fedratinib

http://idrblab.net/ttd/data/drug/details/D0G8BM
ClinicalTrials.gov

https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use

https://clinicaltrials.gov/
Nature Chemical Biology

https://pubchem.ncbi.nlm.nih.gov/substance/172131313
European Medicines Agency (EMA)

https://www.ema.europa.eu/en/about-us/legal-notice

Inrebic (EMEA/H/C/005026)

https://www.ema.europa.eu/en/medicines/human/EPAR/inrebic
EU Clinical Trials Register

https://www.clinicaltrialsregister.eu/
FDA Orange Book

https://www.fda.gov/about-fda/about-website/website-policies#linking

https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
WHO Anatomical Therapeutic Chemical (ATC) Classification

https://www.whocc.no/copyright_disclaimer/

https://www.whocc.no/atc/

ATC Code

https://www.whocc.no/atc_ddd_index/
FDA Medication Guides

https://www.fda.gov/about-fda/about-website/website-policies#linking

Inrebic

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=medguide.page
Human Metabolome Database (HMDB)

http://www.hmdb.ca/citing

Fedratinib

http://www.hmdb.ca/metabolites/HMDB0247668
NCI Cancer Drugs

LICENSE

https://www.cancer.gov/policies/copyright-reuse

Fedratinib Hydrochloride

https://www.cancer.gov/about-cancer/treatment/drugs/fedratinibhydrochloride
NLM RxNorm Terminology

https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html

fedratinib

https://rxnav.nlm.nih.gov/id/rxnorm/2197490
Protein Data Bank in Europe (PDBe)

http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/2TA
PubChem

https://pubchem.ncbi.nlm.nih.gov
RCSB Protein Data Bank (RCSB PDB)

https://www.rcsb.org/pages/policies

https://www.rcsb.org/
Springer Nature

https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=37054073-795242371
Thieme Chemistry

https://creativecommons.org/licenses/by-nc-nd/4.0/

https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=37054073-795242371
Wikidata

https://creativecommons.org/publicdomain/zero/1.0/

Fedratinib

https://www.wikidata.org/wiki/Q7670147
Medical Subject Headings (MeSH)

https://www.nlm.nih.gov/copyright.html

Fedratinib

https://www.ncbi.nlm.nih.gov/mesh/67528327

MeSH Tree

http://www.nlm.nih.gov/mesh/meshhome.html
KEGG

https://www.kegg.jp/kegg/legal.html

Anatomical Therapeutic Chemical (ATC) classification

http://www.genome.jp/kegg-bin/get_htext?br08303.keg

Target-based classification of drugs

http://www.genome.jp/kegg-bin/get_htext?br08310.keg

Drug Groups

http://www.genome.jp/kegg-bin/get_htext?br08330.keg
UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS)

GHS Classification Tree

http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
NORMAN Suspect List Exchange

https://creativecommons.org/licenses/by/4.0/

NORMAN Suspect List Exchange Classification

https://www.norman-network.com/nds/SLE/
National Drug Code (NDC) Directory

https://www.fda.gov/about-fda/about-website/website-policies#linking

FDA Drug Type and Pharmacologic Classification

https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
PATENTSCOPE (WIPO)

SID 391188859

https://pubchem.ncbi.nlm.nih.gov/substance/391188859

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

Write when the problem started and how it changed.
Bring old prescriptions, investigation reports, and current medicines.
Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

What is the most likely cause of my symptoms?
Which danger signs mean I should go to hospital quickly?
Which tests are necessary now, and which can wait?
How should I take medicines safely and what side effects should I watch for?
When should I come for follow-up?

Tests to discuss

Vital signs: temperature, pulse, blood pressure, oxygen saturation
Basic physical examination by a clinician
CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

Avoid heavy lifting, sudden bending, and prolonged bed rest.
Use comfortable posture and gentle movement as tolerated.
Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

Do not start antibiotics without a proper medical decision.
Do not use steroid tablets or injections casually for quick relief.
Do not delay emergency care because of home remedies.

Get urgent help if

Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.

Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician

Tests to discuss with doctor

Temperature chart and hydration assessment
CBC with platelet count if fever persists or dengue/other infection is possible
Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated

Questions to ask

What is the most likely cause of my symptoms?
Which warning signs mean I should go to emergency care?
Which tests are really needed now?
Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Go to emergency care if you notice:

Severe or rapidly worsening symptoms
Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration

Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.

Step 1
Check danger signs first

If danger signs are present, seek emergency care and do not wait for online information.
Step 2
Record the symptom story

Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.
Step 3
Visit a qualified clinician

A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.
Step 4
Do only useful tests

Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.
Step 5
Follow up and return early if worse

If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips

Take a written symptom diary and all previous prescriptions/test reports.
Do not hide medicines already taken, even herbal or over-the-counter medicines.
Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

Internal learning pathway

Explore related RX articles

Related guides from RX Harun are grouped to help readers move from overview to symptoms, tests, treatment, and safe next steps.

Drugs (A - Z)

Vasodilator Drugs Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium…
Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine…
Methamphetamine – Uses, Dosage, Side Effects, Interactions Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.…
Vitamin D3 – Uses, Dosage, Side Effects, Interactions DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from…
Imidazole – Uses, Dosage, Side Effects, Interactions DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of…
Carbimazole Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is…

Read, save, and share this guide

Article Summary

Key Takeaways

RX Patient Tools

Mechanism of Action

Indications

Use in Cancer

Contraindications

Dosage?

Myelofibrosis

Dose Adjustments

Side Effects

The Most Common

More common

Rare

Drug Interactions

Pregnancy and Lactation

Pregnancy

Lactation

How should this medicine be used?

Other uses for this medicine

What special precautions should I follow?

Before taking fedratinib,

Related medical topics

Related Articles

Prepare before seeing a doctor

Which doctor may help?

What to tell the doctor

Questions to ask

Tests to discuss

Avoid these mistakes

Medicine safety and first-aid guide

Safe first steps

OTC medicine safety

Avoid these mistakes

Get urgent help if

Patient health record and symptom diary

Care roadmap for: Fedratinib – Uses, Dosage, Side Effects, Interaction

Check danger signs first

Record the symptom story

Visit a qualified clinician

Do only useful tests

Follow up and return early if worse

Explore related RX articles

To Get Daily Health Newsletter

Dosage